AstraZeneca signed on PsychoGenics to evaluate a number of its drug candidates for their potential to treat psychiatric disorders. The company will use its high-throughput drug discovery platforms that combine behavioral neurobiology with robotics, bioinformatics, and computer vision.
PsychoGenics will receive research payments and milestones commensurate with the stage of development. The company is also entitled to royalties on any future sales.
